Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Digoxin 125micrograms/5ml oral liquid
0201010F0AAANAN
|
Digoxin | Digoxin | Cardiovascular System | No data available |
|
Digoxin 250micrograms/5ml oral liquid
0201010F0AAAPAP
|
Digoxin | Digoxin | Cardiovascular System | No data available |
|
Digoxin 500micrograms/2ml solution for infusion ampoules
0201010F0AAACAC
|
Digoxin | Digoxin | Cardiovascular System | No data available |
|
Digoxin 75micrograms/5ml oral liquid
0201010F0AAAQAQ
|
Digoxin | Digoxin | Cardiovascular System | No data available |
|
Digoxin-specific antibody fragments 38mg inf vials
0201010AAAAAAAA
|
Digoxin antibody | Digoxin antibody | Cardiovascular System | No data available |
|
Digoxin-specific antibody fragments 40mg inf vials
0201010AAAAABAB
|
Digoxin antibody | Digoxin antibody | Cardiovascular System | No data available |
|
Dihydrocodeine 15mg/5ml oral solution
0407020G0AAANAN
|
Dihydrocodeine tartrate | Dihydrocodeine tartrate | Central Nervous System | No data available |
|
Dihydrocodeine 30mg/5ml oral solution
0407020G0AAAMAM
|
Dihydrocodeine tartrate | Dihydrocodeine tartrate | Central Nervous System | No data available |
|
Dihydrocodeine 50mg/1ml solution for injection ampoules
0407020G0AAABAB
|
Dihydrocodeine tartrate | Dihydrocodeine tartrate | Central Nervous System | No data available |
|
Dihydrocodeine 60mg/5ml oral liquid
0407020G0AAARAR
|
Dihydrocodeine tartrate | Dihydrocodeine tartrate | Central Nervous System | No data available |
|
Dihydrocodeine 90mg/5ml oral solution
0407020G0AAAKAK
|
Dihydrocodeine tartrate | Dihydrocodeine tartrate | Central Nervous System | No data available |
|
Dihydrotachysterol 250micrograms/ml oral solution sugar free
0906040K0AAAAAA
|
Dihydrotachysterol | Dihydrotachysterol | Nutrition and Blood | No data available |
|
Dilacort 2.5mg gastro-resistant tablets (Auden McKenzie)
0603020T0BKAAAF
|
Dilacort (Auden Mckenzie) | Prednisolone | Endocrine System | No data available |
|
Dilacort 2.5mg gastro-resistant tablets (Teva)
0603020T0BPAAAF
|
Dilacort (Teva UK Ltd) | Prednisolone | Endocrine System | No data available |
|
Dilacort 5mg gastro-resistant tablets (Auden McKenzie)
0603020T0BKABAG
|
Dilacort (Auden Mckenzie) | Prednisolone | Endocrine System | No data available |
|
Dilacort 5mg gastro-resistant tablets (Teva)
0603020T0BPABAG
|
Dilacort (Teva UK Ltd) | Prednisolone | Endocrine System | No data available |
|
Dilantin-30 suspension
0408010Z0BCABAA
|
Dilantin | Phenytoin | Central Nervous System | No data available |
|
Dill water concentrated
190601000AAAJAJ
|
Generic compound preparation BNF 1906010 | Other concentrated water preparations | Other Drugs and Preparations | No data available |
|
Diloxanide 10mg/5ml oral liquid
0504020G0AAAFAF
|
Diloxanide furoate | Diloxanide furoate | Infections | No data available |
|
Diloxanide 40mg/5ml oral liquid
0504020G0AAAIAI
|
Diloxanide furoate | Diloxanide furoate | Infections | No data available |
|
Diloxanide 500mg tablets
0504020G0AAAAAA
|
Diloxanide furoate | Diloxanide furoate | Infections | No data available |
|
Diloxanide 50mg/5ml oral liquid
0504020G0AAAGAG
|
Diloxanide furoate | Diloxanide furoate | Infections | No data available |
|
Diloxanide 90mg/5ml oral liquid
0504020G0AAAHAH
|
Diloxanide furoate | Diloxanide furoate | Infections | No data available |
|
Diltiazem 0.4% cream
0107010AAAAAIAI
|
Diltiazem hydrochloride (Haemorrhoids) | Diltiazem hydrochloride | Gastro-Intestinal System | No data available |
|
Diltiazem 0.4% ointment
0107010AAAAAQAQ
|
Diltiazem hydrochloride (Haemorrhoids) | Diltiazem hydrochloride | Gastro-Intestinal System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.